Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

被引：0
|
作者：
Lori J. Goldstein
Raymond P. Perez
Denise Yardley
Linda K. Han
James M. Reuben
Hui Gao
Susan McCanna
Beth Butler
Pier Adelchi Ruffini
Yi Liu
Roberto R. Rosato
Jenny C. Chang
机构：
[1] The Hospital of Fox Chase Cancer Center,Department of Medical Oncology
[2] University of Kansas Medical Research Center,Department of Hematopathology–Research
[3] Current address: Early Oncology Development,undefined
[4] Bristol-Myers Squibb,undefined
[5] Tennessee Oncology,undefined
[6] Indiana University Simon Cancer Center,undefined
[7] Current address: Parkview Cancer Institute,undefined
[8] MD Anderson Cancer Center,undefined
[9] Research and Development,undefined
[10] Dompé farmaceutici S.p.A.,undefined
[11] The Methodist Hospital Research Institute,undefined
[12] Sarah Cannon Research Institute,undefined
来源：
Breast Cancer Research | / 22卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
An amendment to this paper has been published and can be accessed via the original article.
引用
收藏
相关论文
共 50 条
  • [21] HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises
    Baltogiannis, Georgios
    Katsios, Christos
    Zografos, George C.
    Roukos, Dimitrios H.
    ANNALS OF SURGICAL ONCOLOGY, 2010, 17 (06) : 1720 - 1720
  • [22] Reparixin, an Inhibitor of CXCR1 and CXCR2 Receptor Activation, Attenuates Blood Pressure and Hypertension-Related Mediators Expression in Spontaneously Hypertensive Rats
    Kim, Hye Young
    Choi, Jin Hee
    Kang, Young Jin
    Park, So Young
    Choi, Hyoung Chul
    Kim, Hee Sun
    BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2011, 34 (01) : 120 - 127
  • [23] HER-2-Negative Breast Cancer Limitations and Next-Generation Sequencing Technology Promises
    Georgios Baltogiannis
    Christos Katsios
    George C. Zografos
    Dimitrios H. Roukos
    Annals of Surgical Oncology, 2010, 17 : 1720 - 1720
  • [24] Effect of bevacizumab combined with docetaxel in the treatment of HER-2-negative recurrent metastatic breast cancer
    Wu, Ming
    Gong, Jianming
    Yu, Wei
    Geng, Jinhong
    Zeng, Linwen
    Kong, Xiangdong
    JOURNAL OF BUON, 2020, 25 (04): : 1814 - 1820
  • [25] A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study
    Neven, Patrick
    Stahl, Nicole
    Vidal, Maria
    Martin, Miguel
    Kaufman, Peter A.
    Harbeck, Nadia
    Hunt, Kelly K.
    Carter, Stacey
    Bidard, Francois-Clement
    Fasching, Peter A.
    Aftimos, Philippe
    Wheatley, Duncan
    Hamilton, Erika
    Aft, Rebecca
    Kulkarni, Swati
    Schmid, Peter
    Bhave, Manali
    Ismail-Khan, Roohi
    Karacsonyi, Claudia
    Estrem, Shawn T.
    Nguyen, Bastien
    Ozbek, Umut
    Yuen, Eunice
    Rodrik-Outmezguine, Vanessa
    Ciruelos, Eva
    CLINICAL CANCER RESEARCH, 2024, 30 (23) : 5304 - 5313
  • [26] A preoperative window-of-opportunity (WOO) study of imlunestrant in ER+, HER2-early breast cancer (EBC): Final analysis from EMBER-2
    Neven, P.
    Stahl, N.
    Losada, M. J. Vidal
    Jimenez, M. Martin
    Kaufman, P. A.
    Harbeck, N.
    Hunt, K.
    Carter, S. A.
    Bidard, F. C.
    Fasching, P.
    Aftimos, P. G.
    Wheatley, D.
    Hamilton, E. P.
    Aft, R.
    Kulkarni, S.
    Ismail-Khan, R.
    Karacsonyi, C.
    Estrem, S. T.
    Ozbek, U.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2023, 34 : S292 - S293
  • [27] KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer
    Pan, Chuanmeng
    Bhandari, Adheesh
    Liu, Yehuan
    Xia, Erjie
    Lin, Lizhi
    Lv, Shixu
    Wang, Ouchen
    HUMAN CELL, 2019, 32 (02) : 172 - 184
  • [28] The therapeutic potential of natural metabolites in targeting endocrine-independent HER-2-negative breast cancer
    Pueskuellueoglu, Miroslawa
    Michalak, Izabela
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [29] Factors associated with CDK 4/6 inhibitor use for patients with advanced, hormone positive, HER-2-negative breast cancer.
    Weldon, Christine B.
    Trosman, Julia R.
    Li, Xi
    Gradishar, William John
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [30] KLP-PI: a new prognostic index for luminal B HER-2-negative breast cancer
    Chuanmeng Pan
    Adheesh Bhandari
    Yehuan Liu
    Erjie Xia
    Lizhi Lin
    Shixu Lv
    Ouchen Wang
    Human Cell, 2019, 32 : 172 - 184
12345